IMMU — Mendus AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK346.22m
- SEK304.26m
Brief: Immunicum Secures Partner On Potential Production Of DCP-001
Brief: Mendus To Report Positive Clinical And Preclinical Data In Ovarian Cancer At ESGO 2022 Congress
Brief: Mendus To Receive Final Payment As Result Of Completion Of The EU Horizon 2020 AML-Vaccin Project
Brief: Mendus Q2 Losss Narrows To SEK 29.3 Mln
Brief: Mendus (previously Immunicum) Announces Financing Commitments Totaling Up To SEK 250 Mln With partners
Brief: Mendus Enters Financing Commitments Totaling Up To SEK 250 Mln With Van Herk Investments And Negma Group
Brief: Immunicum Gets FDA Orphan Drug Designation For Ilixadencel
Brief: Immunicum Q1 Loss At SEK 27.6 Mln
Brief: Immunicum To Participate In Cancer Research Consortium
Brief: Immunicum Q4 Loss For The Period Narrows To SEK 32.8 Mln
Brief: Immunicum Transfers Patent Rights For Modified Adenovirus To Elicera Therapeutics
Brief: Elicera Therapeutics Acquirer Patent From Immunicum
Brief: Immunicum Q3 Loss For The Period Widens To SEK 26.9 Mln
Brief: Immunicum Appoints Lotta Ferm As Chief Financial Officer
Brief: Immunicum Q2 Pre-Tax Loss Widens To SEK 32.1 Million
Brief: Immunicum: Positive Review By Data Safety Monitoring Board For Phase Ib Part Of ILIAD Study
Brief: Immunicum AB Successfully Completed A Directed Share Issue Of 33,233,433 Shares At A Subscription Price Of Sek 4.25 Per Share
Brief: Immunicum AB q1 Diluted Loss Per Share 0.16 Sek
Brief: Immunicum Initiates Research Collaboration With Icahn School Of Medicine At Mount Sinai